lenalidomide - 搜索视频

Therapy for Newly Diagnosed Myeloma - Role of Transplant and MRD, DARA-VRd vs.VRd Trial, Lenalidomide Maintenance Therapy, Achieving MRD- with ASCT and Adding Isatuximab to VRd

Therapy for Newly Diagnosed Myeloma - Role of Transplant and MRD, DARA-VRd vs.VRd Trial, Lenalidomide Maintenance Therapy, Achieving MRD- with ASCT and Adding Isatuximab to VRd

2019年6月8日

Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7) | OncLive

Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7) | OncLive

2025年1月30日

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Newly Diagnosed Multiple Myeloma (NDMM): Outcomes in Patients with 1q21⁺ Status in the Phase 3 IMROZ Study | OncLive

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Newly Diagnosed Multiple Myeloma (NDMM): Outcomes in Patients with 1q21⁺ Status in the Phase 3 IMROZ Study | OncLive

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 MAIA Study | OncLive

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 MAIA Study | OncLive

2022年12月22日

Daratumumab Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study | OncLive

Daratumumab Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study | OncLive

2024年10月14日

Dr Anderson on Daratumumab/Lenalidomide Maintenance After ASCT in Newly Diagnosed Myeloma | OncLive

Dr Anderson on Daratumumab/Lenalidomide Maintenance After ASCT in Newly Diagnosed Myeloma | OncLive

$Dr Mateos on Long-Term OS Data From the Phase 3 CARTITUDE-4 Study of Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma | OncLive$

Dr Mateos on Long-Term OS Data From the Phase 3 CARTITUDE-4 Study of Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma | OncLive

2025年4月1日

La FDA approuve le daratumumab et l'hyaluronidase-fihj associés au bortézomib, à la lénalidomide et à la dexaméthasone pour le traitement du myélome multiple nouvellement diagnostiqué

Clinical Experience Using Tafasitamab Plus Lenalidomide in DLBCL | OncLive

2025年2月4日

Tecvayli monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide

marketscreener.com

EPCORE FL-1: Phase 3 Trial of Subcutaneous Epcoritamab With Rituximab and Lenalidomide (R2) vs R2 Alone in Patients With Relapsed or Refractory Follicular Lymphoma | OncLive

2024年1月23日

Next-Generation Therapies Target High-Risk Smoldering Multiple Myeloma: Paula Rodríguez-Otero, MD, PhD | AJMC

Dr. Diefenbach on Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in FL | OncLive

2020年1月27日

VIDEO: Four drugs 'appear to be better' in treatment of newly diagnosed multiple myeloma

Results of the Phase III Randomized IsKia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone as Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients | OncLive

2023年12月21日

Tafasitamab Lenalidomide vs. CIT for Transplant-Ineligible R/R DLBCL

已浏览 354 次2024年9月30日

Tafasitamab Lenalidomide Therapy in Relapsed/Refractory DLBCL | OncLive

2023年6月26日

Lenalidomide: Uses, Dosage, Side effects, Precautions, Interactions - Drug Medication Video - Medindia

2025年1月24日

Dr Mateos on Ongoing Research With Cilta-Cel in Newly Diagnosed Multiple Myeloma | OncLive

2025年4月9日

Dr. Richard on the Benefit of Adding Daratumumab to Standard-of-Care Rd in Myeloma | OncLive

2020年9月8日

Development of a Low-dose Percutaneous Delivery System Lenalidomide for Hematologic Malignancies: The Journey from Ideation to Phase 2

Dr Mehta on the FDA Approval of Tafasitamab Plus Rituximab/Lenalidomide in R/R Follicular Lymphoma | OncLive

10 个月之前

Efeitos colaterais de Revlimid (lenalidomide), interações, usos e impressão de drogas - Saúde 2026

2019年8月21日

FDA Approves Tafasitamab Plus Lenalidomide and Rituximab for R/R Follicular Lymphoma | OncLive

10 个月之前

Novartis' Sandoz Launches Generic Lenalidomide in Europe

2022年2月18日

marketscreener.com

Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk

2024年4月24日

Dr Dhakal on Survival and Safety Outcomes With Cilta-Cel in R/R Myeloma | OncLive

2024年10月2日

Dr. Stewart on the Safety Profile of Carfilzomib in Multiple Myeloma Patients | OncLive

2015年1月20日

Sanofi's Sarclisa Combination Gets EU Approval For Treating Newly Diagnosed Multiple Myeloma

finanznachrichten.de

展开